GlassScriptPhysician profile
Hillary H Tran
NPI 1497886444
$5,005.18
in general payments reported to CMS, 2019-2025
26 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $251 · 2021: $365 · 2022: $527 · 2023: $866 · 2024: $448 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222 · Travel and Lodging: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.32 |
| Travel and Lodging | $1,007.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,255.99 | 2025 | Renal - Chronic |
| Astrazeneca Pharmaceuticals LP | $666.08 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $509.85 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $396.71 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $363.08 | 2023-2025 | Tarpeyo |
| Amarin Pharma, INC. | $230.25 | 2019 | |
| Mallinckrodt Hospital Products INC. | $176.02 | 2023-2024 | Acthar |
| Akebia Therapeutics INC | $175.96 | 2019-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $158.27 | 2020-2024 | Rayaldee |
| Travere Therapeutics, INC. | $141.80 | 2023 | |
| Daiichi Sankyo INC. | $124.37 | 2023 | Injectafer |
| Mallinckrodt Enterprises LLC | $119.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $107.38 | 2020 | |
| Glaxosmithkline, LLC. | $106.39 | 2021-2022 | |
| Amgen INC. | $92.91 | 2021-2025 | Tavneos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $66.30 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $58.95 | 2020-2022 | |
| Novo Nordisk INC | $58.29 | 2021-2025 | Rybelsus, Ozempic |
| Aurinia Pharma U.S., INC. | $49.35 | 2022-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $31.49 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2022 | |
| Vanda Pharmaceuticals INC. | $25.66 | 2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $21.21 | 2023 | Jynarque |
| Bard Peripheral Vascular, INC. | $14.02 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.38 | 2024 | Purified Cortrophin Gel |
| Emergent Biosolutions INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.